

**SUPRIYA LIFESCIENCE LIMITED**

CIN: L51900MH2008PLC180452


Registered Office: 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

**Part I -Statement of Standalone Unaudited Financial Results for the Quarter Ended June 30, 2022**

Rs. in Millions, except per share data

Particulars	Quarter ended 30-06-2022 Unaudited	Quarter ended 31-03-2022 Audited	Quarter ended 30-06-2021 Unaudited	Year ended 31-03-2022 Audited
<b>Income</b>				
Revenue from Operations	1,013.55	1,812.69	769.42	5,300.49
Other Income	23.57	38.55	19.39	75.77
<b>Total Income</b>	<b>1,037.12</b>	<b>1,851.24</b>	<b>788.81</b>	<b>5,376.26</b>
<b>Expenses</b>				
a) Cost of Materials Consumed	425.85	382.42	419.25	1,988.30
b) Purchase of Stock in Trade	-	-	-	-
c) Change in inventories of finished goods , work in progress & stock in trade.	-75.72	325.89	-23.58	-30.26
d. Employee benefit expenses	126.70	128.69	83.76	490.78
e. Finance Cost	5.81	10.17	9.74	41.98
f. Depreciation & amortisation expense	28.85	25.79	24.77	101.18
g. Other expenditure	224.26	223.46	135.46	711.82
<b>Total Expenses</b>	<b>735.76</b>	<b>1,096.43</b>	<b>649.40</b>	<b>3,303.81</b>
<b>Profit/(loss) before Exceptional Items &amp; Tax</b>	<b>301.36</b>	<b>754.81</b>	<b>139.41</b>	<b>2,072.45</b>
Exceptional Items	-	-	-	-
<b>Profit/(loss) before Tax</b>	<b>301.36</b>	<b>754.81</b>	<b>139.41</b>	<b>2,072.45</b>
<b>Tax Expense</b>				
a) Current Tax	45.87	184.45	16.05	521.89
b) Deferred Tax	3.00	108.25	45.97	32.46
<b>Total Tax Expense</b>	<b>48.87</b>	<b>292.70</b>	<b>62.02</b>	<b>554.35</b>
<b>Profit/(Loss) for the period</b>	<b>252.49</b>	<b>462.11</b>	<b>77.39</b>	<b>1,518.10</b>
Other Comprehensive Income				
A (i) Items that will not be reclassified to profit or loss	-9.86	1.55	0.06	-4.22
(ii) Income Tax relating to items that will not be reclassified to profit or loss	2.48	-0.37	-0.02	1.08
B (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>Total Other Comprehensive Income for the period</b>	<b>-7.38</b>	<b>1.17</b>	<b>0.04</b>	<b>-3.15</b>
<b>Total Comprehensive Income for the period</b>	<b>245.11</b>	<b>463.28</b>	<b>77.43</b>	<b>1,514.95</b>
Earnings per equity Share (for continuing operation):				
(1) Basic	3.14	5.74	0.96	18.86
(2) Diluted	3.14	5.74	0.96	18.86
Earnings per equity Share (for discontinued operation):				
(1) Basic	-	-	-	-
(2) Diluted	-	-	-	-
Earnings per equity Share (for discontinued & continuing operations):				
(1) Basic	3.14	5.74	0.96	18.86
(2) Diluted	3.14	5.74	0.96	18.86




**Notes:-**

1. The Unaudited Standalone financial results of the Company for the quarter ended June 30, 2022 have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above Unaudited standalone financial results of the Company for the quarter ended June 30, 2022 have been reviewed by the Audit Committee on August 12, 2022 and thereafter approved by the Board of Directors at their meeting held on August 12, 2022.
3. The Statutory Auditor have submitted Limited Review Report on the above Unaudited Financial Results for Quarter ended June 30, 2022.
4. The figures of the previous periods have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the board of directors of  
Supriya Lifescience Limited**



  
**Saloni Wagh**  
**Whole Time Director**  
**DIN: 08491410**

**Place :- Mumbai**  
**Date :- August 12, 2022**



# **KAKARIA AND ASSOCIATES LLP**

CHARTERED ACCOUNTANTS

UJWAL K. KAKARIA B.Com., B.L., F.C.A.

SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.

JAIPRAKASH H. SHETHIYA B.Com., F.C.A.

YOUR REF. :

OUR REF. :

## **Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,

Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 30<sup>th</sup> June ,2022, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been compiled from the related IND AS Financial Statements which has been prepared in accordance with Indian Accounting Standards prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,

Mumbai - 400 053 Tel: 022 26744670. Email: [mumbai@kakariaassociates.com](mailto:mumbai@kakariaassociates.com),

Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)



perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14<sup>th</sup> October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For,**  
**Kakaria and Associates LLP**  
**Chartered Accountants.**  
**FRN: 104558W/ W100601**



**CA. Ujwal K. Kakaria**  
**Partner**  
**Membership No. – 035416**  
**Place: - Mumbai**  
**Date: - 12/08/2022**  
**UDIN: - 22035416AOXTAB2321**





**SUPRIYA LIFESCIENCE LTD.**

*Creating true values that bind global health*

**Brief disclosures of Statutory Auditor on reappointment as required vide SEBI Circular CIRICFDICMD/4/2015 dated September 9, 2015 has been provided below:**

Name of the Statutory Auditor	M/s. Kakaria & Associates LLP, Chartered Accountants
Reason for change viz. appointment, resignation, removal, death or otherwise	M/s. Kakaria & Associates LLP, Chartered Accountants are reappointed as the Statutory Auditors of the Company, subject to approval of the members at the ensuing 14th AGM.
Date and Term of appointment	M/s. Kakaria & Associates LLP, Chartered Accountants are reappointed as the Statutory Auditors of the Company for a second term of five consecutive years i.e. to hold office from the conclusion of the 14th Annual General Meeting until the conclusion of 19th Annual General Meeting subject to the approval of the shareholders of the Company.
Brief Profile	M/s. Kakaria & Associates LLP, is a leading Chartered Accountancy firm in Mumbai, led by skilled and experienced Indian Chartered Accountants having industry experience of over a decade. The Firm provides services in the areas of Income Tax, GST, Audit & assurance, Accounts, Company secretary, Cost accountancy/audit, Finance, and Personal/corporate financial planning along with a host of other financial services with its head office at Vapi, Gujarat and branches at Mumbai, Boisar, Dahanu and Umbergaon.
Disclosure of Relationship Directors	Not Applicable



**Corporate Office :** 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai 400 063, Maharashtra, India.

Tel : +91 22 40332727 / 66942507 | Fax : +91 22 26860011 | GSTIN : 27AALCS8686A1ZX

**CIN: L51900MH2008PLC180452** | E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) | Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory**

**: A-5/2, Lote Parshuram Industrial Area, M.I.D.C., Tal.-Khed, Dist. Ratnagiri, Pin: 415 722, Maharashtra, India.**

Tel: +91 2356 272299 | Fax : +91 2356 272178 | E-Mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**GOVT. RECOGNISED EXPORT HOUSE**